Focus Partners Wealth
TSHA icon

Focus Partners Wealth’s Taysha Gene Therapies TSHA Stock Holding History

Focus Partners Wealth’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-295,516
Closed -$1.63M – 2834
2025
Q4 		$1.63M Buy
+295,516
New +$1.44M ﹤0.01% 1418

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Focus Partners Wealth's TSHA Position: Q1 2026 in Review

Focus Partners Wealth sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 295,516 shares — an estimated $1.63M sold.

Focus Partners Wealth first reported a position in TSHA in Q4 2025 and held it in 1 quarter. The position peaked at $1.63M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Focus Partners Wealth reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 295,516 Taysha Gene Therapies shares in Q1 2026, an estimated $1.63M.
  • Focus Partners Wealth first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Taysha Gene Therapies position peaked at $1.63M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.